It is expected that large numbers of healthcare workers will experience a broad range of psychological reactions and symptoms including anxiety, depression, moral distress, and trauma symptoms that will cause both significant suffering as well as occupational and social impairment. The purpose of this study is to find interventions which are helpful in treating psychological distress in healthcare workers caring for COVID-19 patients. There are two phases of the study. All participants will take part in Phase I, which consists of 4 sessions over a two-week period of either a narrative writing intervention or a medical music intervention. Participants will be randomly assigned to the narrative writing intervention or medical music intervention. After Phase I, participants will be re-assessed. Healthcare workers who meet criteria for PTSD will be given the option to participate in Phase II of the study, in which they will be offered a choice between one of two evidence-based treatments for PTSD: Interpersonal Therapy (IPT) or Exposure Therapy (ET). Both treatments are comprised of ten 75-minute sessions scheduled twice weekly. Participants will be allowed to choose a preferred treatment in Phase II. After Phase II participants will complete a final assessment concluding the study. All interventions will be offered using distance technology.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Feasibility Indicator: Recruitment (Phase I)
Timeframe: Baseline
Feasibility Indicator: Recruitment (Phase II)
Timeframe: Post-Phase I Assessment at week 2
Feasibility Indicator: Enrollment (Phase I)
Timeframe: Baseline
Feasibility Indicator: Enrollment (Phase II)
Timeframe: Post-Phase I Assessment at approximately week 2
Feasibility Indicator: Retention (Phase I)
Timeframe: Post-Phase I Assessment at approximately week 2
Feasibility Indicator: Retention (Phase II)
Timeframe: Post-Phase II Assessment at approximately week 7
Acceptability Indicator: Satisfaction (Phase I)
Timeframe: Post-Phase I Assessment at approximately week 2
Acceptability Indicator: Satisfaction (Phase II)
Timeframe: Post-Phase II Assessment at approximately week 7
Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase I)
Timeframe: Start of Phase I to approximately 2 weeks
Preliminary Efficacy as Measured by Change in Clinician-Administered PTSD Scale Score (Phase II)
Timeframe: Start of Phase II to approximately 5 weeks